Quantification of increased biologically active CXCL12α plasma concentrations after ACKR3 antagonist treatment in humans

• Main Authors: Peter Blattmann (Author), Hervé Farine (Author), Brian Dan (Author), Nicole Stiffler (Author), Thomas Lefebvre (Author), Christine Huynh (Author), Patricia N. Sidharta (Author), Jasper Dingemanse (Author), Richard W. D. Welford (Author), Marcel Keller (Author), Daniel S. Strasser (Author)
• Format: Book
• Published: Wiley, 2024-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract CXCL12 acts as a chemoattractant by binding to the receptor CXCR4. The (atypical) chemokine receptor ACKR3 (CXCR7) scavenges CXCL12. Antagonism of ACKR3 thus leads to an increase in CXCL12 concentrations that has been used as a pharmacodynamic biomarker in healthy adults. Increased CXCL12 c...